Cargando…

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR inhibitors. Mutations in the EGFR kinase domain predict sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borràs, Emma, Jurado, Ismael, Hernan, Imma, Gamundi, María José, Dias, Miguel, Martí, Isabel, Mañé, Begoña, Arcusa, Àngels, Agúndez, José AG, Blanca, Miguel, Carballo, Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192787/ https://www.ncbi.nlm.nih.gov/pubmed/21943394 http://dx.doi.org/10.1186/1471-2407-11-406

Ejemplares similares

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity
por: Borràs, Emma, et al.
Publicado: (2013)

Detection of novel mutations that cause autosomal dominant retinitis pigmentosa in candidate genes by long-range PCR amplification and next-generation sequencing
por: Dias, Miguel de Sousa, et al.
Publicado: (2013)

Survey of familial glaucoma shows a high incidence of cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) mutations in non-consanguineous congenital forms in a Spanish population
por: Millá, Elena, et al.
Publicado: (2013)

New COL6A6 variant detected by whole-exome sequencing is linked to break points in intron 4 and 3′-UTR, deleting exon 5 of RHO, and causing adRP
por: de Sousa Dias, Miguel, et al.
Publicado: (2015)

Novel LMX1B mutation in familial nail-patella syndrome with variable expression of open angle glaucoma
por: Millá, Elena, et al.
Publicado: (2007)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
por: Shen, Shanxiang, et al.
Publicado: (2012)

KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review
por: Shigaki, Hironobu, et al.
Publicado: (2012)

High prevalence of mutations in peripherin/RDS in autosomal dominant macular dystrophies in a Spanish population
por: Gamundi, María José, et al.
Publicado: (2007)

Pharmacogenomics of Prostaglandin and Leukotriene Receptors
por: Cornejo-García, José A., et al.
Publicado: (2016)

Three novel and the common Arg677Ter RP1 protein truncating mutations causing autosomal dominant retinitis pigmentosa in a Spanish population
por: Gamundi, María José, et al.
Publicado: (2006)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
por: Agúndez, José A. G., et al.
Publicado: (2022)

A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing
por: Mack, Elisabeth, et al.
Publicado: (2016)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers
por: Niya, Mohammad Hadi Karbalaie, et al.
Publicado: (2016)

Editorial: NSAIDs Pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2021)

Phenotypic Description of the Spanish Multicentre Genetic Glaucoma Group Cohort
por: Milla, Elena, et al.
Publicado: (2017)

Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2023)

KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
por: Jouini, Raja, et al.
Publicado: (2019)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain
por: Agúndez, José A. G., et al.
Publicado: (2012)

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs
por: Agúndez, José A. G., et al.
Publicado: (2014)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Adding pharmacogenomics to the development of new marine-derived anticancer agents
por: Jimeno, José, et al.
Publicado: (2006)

Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology
por: Garcia-Agundez, Augusto, et al.
Publicado: (2022)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAF(V600)
por: Skorokhod, Alexander, et al.
Publicado: (2013)

"Prevalencia de Echinococcus granulosus en perros, en el Puerto de Veracruz y su diagnóstico como medida preventiva para evitar la zoonosis" /
por: Gamundi Moreno, Miguel
Publicado: (1983)

KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
por: Sundström, Magnus, et al.
Publicado: (2010)

Editorial: The Potential of Machine-learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology: Volume II
por: Garcia-Agundez, Augusto, et al.
Publicado: (2023)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas
por: Jancik, Sylwia, et al.
Publicado: (2012)

Correction: Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAF(V600)
por: Skorokhod, Alexander, et al.
Publicado: (2013)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
por: Lee, Seung Eun, et al.
Publicado: (2016)

A Complex of Pyrosequencing-Based Methods for Detection of Somatic Mutations in Codons 600 and 601 of the BRAF gene
por: Dribnokhodova, O.P., et al.
Publicado: (2022)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Analysis of the melon (Cucumis melo) small RNAome by high-throughput pyrosequencing
por: Gonzalez-Ibeas, Daniel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ukdtuc1iumnq9bj8pgapr4dujn